Haematopoietic stem cell transplantation in Tanzania

Mtenga, Janeth; Orf, Katharine; Zheng, Jiexin; Chamba, Clara; Chuwa, Harrison; Luoga, Frederick; Malangahe, Stella W.; Iversen, Per Ole; Makani, Julie

doi:10.1111/bjh.17106

Cited by 12 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A successful transplantation program's foundation is built on the experience of medical, nursing, and laboratory staff, hospital support, and effective leadership. 10,35 The biggest challenge to establishing the HSCT program in Ethiopia is the lack of transplant doctors, except for a few hematologists, and an abundant middle-level workforce; internists, lab technicians, nurses, and pharmacists.…”

Section: Human Resource Developmentmentioning

confidence: 99%

“…7 However, establishing HSCT service is a high-profile endeavor and continues to be difficult for developing countries due to the expensive investment needed in specialized infrastructure, substantial healthcare professional training, and competing health priorities. [8][9][10] Meanwhile, there are several works of literature from resourceconstrained nations that detail how they launched prosperous, self-sustaining HSCT programs. 8,[11][12][13] To achieve the goal of launching the HSCT facility, it is essential to examine the experience of developing nations and guideline recommendations of open-access journals.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Why and How Should Ethiopia Establish a Stem Cell Transplant Service? A Review Article

Mekonnen¹,

Farris²

2023

BTT

View full text Add to dashboard Cite

Ethiopia is attempting to reduce cancer-related morbidity and mortality through a strategic national cancer control plan but according to Globocan 2020, hematologic malignancies particularly leukemia and non-Hodgkin's lymphoma rank among the top five leading causes of new cancer incidence and cause of death among all age groups in both sexes. Hematopoietic stem-cell transplantation (HSCT) is an advanced treatment modality that makes the only effective treatment for cancer and non-cancer-related hematologic diseases unresponsive to conventional therapy. Patients who need stem cell transplants must travel to abroad countries to get the treatment. Meanwhile, the Ethiopian National Specialty and Subspecialty Roadmap sets the goal of establishing HSCT centers in 2020-2029 GC, yet leaders and planners must start taking steps to put the setup in place. Setting up an HSCT facility is challenging for developing countries due to the high costs, limited infrastructure, and need for intensive medical staff training; however, several nations have been able to start successful stem cell transplant programs. This review summarizes the basic steps and requirements of the program in light of guidelines recommendations and lessons learned from other developing countries. It also highlights possible cost-effective opportunities, bottlenecks, and areas that will require work and investment to make the objective reality in Ethiopia.Provides key information to assist administrators and policymakers to set priorities in planning and making informed decisions to establish and maintain the service.

show abstract

Section: Human Resource Developmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Why and How Should Ethiopia Establish a Stem Cell Transplant Service? A Review Article

Mekonnen¹,

Farris²

2023

BTT

View full text Add to dashboard Cite

show abstract

“…Many tertiary facilities in SSA lack infrastructure and funding to perform HSCT. Access to HSCT is limited to 6 of 54 African countries (South Africa, Nigeria, Morocco, Algeria, Tunisia, and Egypt) [ 183 ], and patients often seek HSCT in India, Canada, and U.S [ 184 ]. Nonetheless, high-burden countries such as Tanzania have accelerated progress in establishing HSCT capabilities through training health professionals both locally and through exchange programs with developed countries; research; establishment of partnerships with community and international organizations and experts in setting up and conducting HSCT; and mobilization of funds [ 184 , 185 ].…”

Section: Comprehensive Care Of Children With Scdmentioning

confidence: 99%

Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond

Egesa

Nakalema

Waibi

et al. 2022

International Journal of Pediatrics

View full text Add to dashboard Cite

Sickle cell disease (SCD) is an umbrella term for a group of life-long debilitating autosomal recessive disorders that are caused by a single-point mutation (Glu→Val) that results in polymerization of hemoglobin (Hb) and reversible sickle-shape deformation of erythrocytes. This leads to increased hemolysis of erythrocytes and microvascular occlusion, ischemia-reperfusion injury, and tissue infarction, ultimately causing multisystem end-organ complications. Sickle cell anemia (HbSS) is the most common and most severe genotype of SCD, followed by HbSC, HbSβ0thalassemia, HbSβ+thalassemia, and rare and benign genotypes. Clinical manifestations of SCD occur early in life, are variable, and are modified by several genetic and environmental factors. Nearly 500 children with SCD continue to die prematurely every day, due to delayed diagnosis and/or lack of access to comprehensive care in sub-Saharan Africa (SSA), a trend that needs to be urgently reversed. Despite proven efficacy in developed countries, newborn screening programs are not universal in SSA. This calls for a consolidated effort to make this possible, through the use of rapid, accurate, and cheap point-of-care test kits which require minimal training. For almost two decades, hydroxyurea (hydroxycarbamide), a century-old drug, was the only disease-modifying therapy approved by the U.S. Food and Drug Administration. Recently, the list expanded to L-glutamine, crizanlizumab, and voxelotor, with several promising novel therapies in the pipeline. Despite its several limitations, hematopoietic stem cell transplant (HSCT) remains the only curative intervention for SCD. Meanwhile, recent advances in gene therapy trials offer a glimpse of hope for the near future, although its use maybe limited to developed countries for several decades.

show abstract

“…Following the article by Mtenga et al 1 . regarding establishing a haematopoietic stem cell transplant (HSCT) service in a resource‐poor environment, we wished to share our experiences in developing an autologous and allogeneic programme in Bangladesh.…”

Section: Autologous Hsct (N = 23) Allogeneic Hsct (N = 3)mentioning

confidence: 99%

Overcoming the hurdles and establishing a haematopoietic stem cell transplant centre in a resource poor setting: an example from Dhaka, Bangladesh

Mahfuz¹,

Hossain²,

Uddin³

et al. 2021

Br J Haematol

View full text Add to dashboard Cite

Haematopoietic stem cell transplantation in Tanzania

Cited by 12 publications

References 31 publications

Why and How Should Ethiopia Establish a Stem Cell Transplant Service? A Review Article

Why and How Should Ethiopia Establish a Stem Cell Transplant Service? A Review Article

Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond

Overcoming the hurdles and establishing a haematopoietic stem cell transplant centre in a resource poor setting: an example from Dhaka, Bangladesh

Contact Info

Product

Resources

About